Effects of cyclin D1 antisense oligodeoxyneucleotides on the growth and expression of G₁ phase regulators in gastric carcinoma cells

Abstract

To investigate the effects of Cyclin D1 antisense oligodeoxyneucleotides (ASODN) on the growth, cell cycle progression and expression of G₁ phase regulators in human gastric carcinoma cell lines SGC7901 and HS746T, phosphorothioate-modified Cyclin D1 ASODN were encapsulated by Lipofect AMINE2000 and transfected into gastric carcinoma cells. Dose-dependent inhibitory effects were induced by Cyclin D1 ASODN in two gastric carcinoma cell lines. Treatment of gastric carcinoma cells with 0.2 μmol/L CycliN D1 ASODN for 24 h could significantly inhibit their growthin vitro andin vivo, reduce expression of Cyclin D1mRNA to 26.3% (SGC7901) and 17.3% (HS746T) respectively. The percentage of cells in G₀/G₁ phase was increased as revealed by flow cytometry. Immunohistochemical staining showed that the expression of p21 was increased and the expression of Cyclin D1 and pRb was decreased in the two cell lines; the expression of p27 was increased in HS746T, but unchanged in SGC7901. Cyclin D1 ASODN could inhibit the growth and the expression of Cyclin D1 mRNA in gastric carcinoma cells, influence the cell cycle and expression of its regulators.

Keywords

gastric carcinoma / Cyclin D1 / antisense oligodeoxyneucleotides / cell cycle

References

[1] ArberN, GammonM D, HibshooshH, et al.. Overex-pression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol, 1999, 30(9): 1087-1087

[2] MullerW, NoguchiT, WirtzH C, et al.. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol, 1999, 189(2): 186-186

[3] OdaK, OkabayashiT, KataokaM, et al.. Evaluation of cyclin D1 mRNA expression in gastric and colorectal cancers. Res Commun Mol Pathol Pharmacol, 1999, 105(3): 237-237

[4] CagnoliM, BarbieriF, BruzzoC, et al.. Control of cyclin D1 expression by antisense oligonucleotides in three ovarian cancer cell lines. Gynecol Oncol, 1998, 70(3): 372-372

[5] GreenW D, RohH, PippinJ, et al.. Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease. J Am Coll Surg, 2000, 191(1): 93-93

[6] SherrC J. Cancer cell cycles. Science, 1996, 274(5293): 1672-1672